James S. Wysock, MD, MSc presented “The Application of Stimulated Raman Histology to Urologic Malignancies – Human and Artificial Intelligent Assessment” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.
How to cite: Wyscock, James S. “The Application of Stimulated Raman Histology to Urologic Malignancies – Human and Artificial Intelligent Assessment” November, 2023. Accessed Aug 2024. https://grandroundsinurology.com/the-application-of-stimulated-raman-histology-to-urologic-malignancies-human-and-artificial-intelligent-assessment/
The Application of Stimulated Raman Histology to Urologic Malignancies – Human and Artificial Intelligent Assessment – Summary
James S. Wysock, MD, MSc, explores Stimulated Raman Histology (SRH) in diagnosing and managing urologic malignancies, emphasizing the role of both human and artificial intelligence (AI) assessments. SRH, a cutting-edge imaging technique, provides rapid, label-free histological images of tissues, enabling real-time intraoperative diagnosis. Dr. Wysock highlights SRH’s high specificity and sensitivity in identifying cancerous tissues, potentially reducing reliance on frozen sections and improving surgical outcomes.
Dr. Wysock discusses integrating AI into SRH image analysis, including creating training datasets, validation studies, and clinical trials. The potential for AI to enhance diagnostic precision and minimize human error is a key focus. Data show that SRH, combined with AI assessment, significantly improves the accuracy of margin detection during prostate and kidney cancer surgeries.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
James S. Wysock, MD, MSc, is an Assistant Professor of Urology at NYU Langone Health and Division Chief of Urology at Bellevue Hospital Center in New York City. He received his undergraduate degree in Chemical Engineering from the University of Illinois- Urbana Champaign and his medical degree from Northwestern University Feinberg School of Medicine. He completed his internship and residency training in urology at New York-Presbyterian Hospital in the Brady Department of Urology at Weill Cornell Medical College. He then completed his fellowship in urologic oncology and robotic surgery at NYU Langone, where he also obtained a Master’s of Clinical Investigation.
At NYU Langone Health and Bellevue Hospital, Dr. Wysock provides clinical services for the diagnosis and management of the breadth of urologic malignancies. His clinical research efforts focus on image-guided prostate cancer diagnosis and treatment, including MRI-US fusion biopsy and partial gland prostate ablation techniques.
